date_range Iraupena 2019(e)ko urria-(a)k 01-(e)tik 2023(e)ko iraila-(a)k 30-(e)ra izan da (48 months) Amaitu

Norgehiagoka-aren araubidean eman da.

Deialdi: INTERREG.18

Ikertzaileak

Foto de José Bruno Celso
José Bruno Celso
Fariña Espinosa
Arduraduna
Foto de María Magdalena
María Magdalena
Echezarreta López
Foto de María Esther
María Esther
Sánchez Sánchez
Foto de Ana María
Ana María
Santoveña Estévez

(10) proiektuarekin lotutako argitalpenak

Erakutsi tipologiaren arabera

2024

  1. Quality assessment of oral antimalarial and antiretroviral medicines used by public health systems in Sahel countries

    PLoS ONE

2023

  1. Quality assessment of antimalarial tablets supplied on the Mauritanian and Spanish markets

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  2. Estudio comparativo del análisis de fármacos antimaláricos con técnicas espectrofotométricas y cromatográficas

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. A pharmaceutical monitoring system to assess the quality of antituberculosis drug products used in Mauritania

    PLoS ONE

2022

  1. Development and Optimization of a New UPLC-UV/MS Method through DoE and MLR for Detecting Substandard Drug Products to Treat Tuberculosis

    Molecules

2021

  1. Pharmaceutical equivalence and stability study of levofloxacin tablets commercialized in Europe and Africa

    XV Congreso de la Sociedad Española de Farmacia Industrial y Galénica

  2. Monitoring system for substandard detection of antituberculosis drugs used in the Mauritanian National Health System

    XV Congreso de la Sociedad Española de Farmacia Industrial y Galénica

  3. Monitoring system for substandard detection of antituberculosis drugs used in the Mauritanian National Health System

    RESCIFAR Revista Española de Ciencias Farmacéuticas

  4. Pharmaceutical equivalence and stability study of levofloxacin tablets commercialized in Europe and Africa

    RESCIFAR Revista Española de Ciencias Farmacéuticas

2020

  1. Stability study of isoniazid and rifampicin oral solutions using hydroxypropyl-Β-cyclodextrin to treat tuberculosis in paediatrics

    Pharmaceutics